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ABSTRACT 
Imatinib mesylate and nilotinib are highly effective at eradicating the majority of chronic myeloid 
leukaemia (CML) cells, however neither agent induces apoptosis of primitive CML CD34+ cells. One 
possible explanation is that CD34+ cells do not accumulate sufficient intracellular drug due to either 
inadequate active uptake or increased efflux. To determine the interaction of nilotinib with major 
clinically implicated drug transporters we investigated interactions with MDR1 (ABCB1), MRP1 
(ABCC1), ABCG2 (BCRP) and hOCT1 in CML cell lines and primitive (CD34+) primary CML cells.  
Nilotinib is neither dependent on active import by hOCT1, nor effluxed via the ABC transporters 
investigated.  Indeed, we found nilotinib to be an inhibitor of hOCT1, MDR1 and ABCG2.  The efflux 
transporters MDR1, MRP1 and ABCG2 are expressed on CML CD34+ cells at 13.5, 108 and 291% of 
control respectively although hOCT1 expression was absent; however, inhibition of efflux transporter 
activity did not potentiate the effect of nilotinib on apoptosis, Bcr-Abl inhibition, or CML CD34+ cell 
proliferation. Therefore, we have found no evidence for either active uptake of nilotinib via hOCT1 or 
efflux via MDR1, MRP1 or ABCG2 and it is therefore unlikely that these transporters will have any 
effect on the clinical response to this drug.   
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INTRODUCTION 
In response to resistance and failure to induce molecular responses in a proportion of chronic 
myeloid leukaemia (CML) patients treated with imatinib (Gleevec®; Glivec®; Novartis) (1,2), new 
tyrosine kinase inhibitors (TKI) have been developed and both nilotinib (Tasigna®; Novartis) and 
dasatinib (Sprycel®; Bristol-Myers Squibb) are now in clinical use (3,4).  Despite the improved potency 
(20-fold) of nilotinib in cell lines and on bulk primary CML cells we have found that nilotinib is no more 
effective than imatinib in inducing apoptosis of primitive CD34+ CML cells (5). Furthermore, we have 
demonstrated that as with imatinib, CD34+ CML cells persist after treatment and that nilotinib is anti-
proliferative rather than pro-apoptotic, resulting in the accumulation of quiescent CD34+ cells (5).  We, 
and others, have proposed that this population of primitive cells which are insensitive to imatinib and 
nilotinib may form a pool of disease in patients under treatment and contribute to the Bcr-Abl 
molecular signal detected in the majority of patients (6, 7). It is therefore this population that must be 
specifically targeted in order to cure rather than control the disease in patients. 
One possible reason for the failure of nilotinib to kill CD34+ primitive CML cells is insufficient 
intracellular levels of the drug owing to inadequate active uptake via the Solute Carrier (SLC) 
transporter family, or to efflux via multidrug resistance proteins of the ATP-binding cassette (ABC) 
family. There has been much debate about the role of ABC transporters in mediating imatinib 
resistance; these include our own investigations into ABCG2 activity in CML CD34+ cells (8). Imatinib 
may be an inhibitor or substrate of ABCG2 depending on its concentration (9-11), but in CD34+ cells, 
at concentrations above clinical trough plasma values (1.2µM), it is an inhibitor (8). Imatinib may also 
be a substrate for MDR1 (ABCB1, P-gp) in cell lines (12-14) however, we have not found this in 
primary CML cells (15).  Further, a number of studies including our own have demonstrated that 
imatinib is actively taken up via the human organic cation transporter 1 (hOCT1; SLC22a1) (12-17) 
and that reduced hOCT1 expression may correlate with a poor clinical response (17). 
To date there have only been two reports that suggest nilotinib may be an ABCG2 substrate 
but is not actively taken up by hOCT1 (18, 19). We have now investigated the interaction of nilotinib 
with the major clinically implicated drug transporters MDR1, MRP1 (ABCC1), ABCG2 and hOCT1 in 
CML cell lines and primary CD34+ cells.  Additionally, we have co-treated these primitive cells with 
nilotinib in the presence of efflux transporter inhibitors to investigate whether this renders the drug 
more effective. 
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MATERIALS AND METHODS 
Reagents.  14C-labelled imatinib (specific activity, 3.386MBq/mg), nilotinib (specific activity, 
3.480MBq/mg), and the MDR1 inhibitor PSC833 were kindly provided by Novartis Pharma (Basel, 
Switzerland).  14C-labelled tetraethylammonium bromide (TEA) (specific activity, 118.4MBq/mmol) was 
purchased from Perkin Elmer Life Sciences (Boston, MA, USA), Gold Star scintillation cocktail from 
Meridian (Epsom, UK).   
 
Cell culture.  Transfection of KCL22 cells with hOCT1 was performed as previously described (20). 
The MDR1-transfected Type II Marin Darby canine kidney (MDCKII) cell line was a kind gift from Prof 
P Borst (Netherlands Cancer Institute) (16). The K562 wild type (WT) and cell lines over-expressing 
MDR1 or MRP1 were donated by Drs T Southgate and L Fairbairn (Paterson Institute for Cancer 
Research, Manchester, UK) (21). ABCG2 over-expressing OCT-AML6.2 cells and the control line 
OCT-AML3 were kindly provided by Dr B Sorrentino (St Jude Children’s Research Hospital, Memphis, 
TN) (8). MDCKII were grown in Dulbecco’s Modified Eagle Medium (DMEM), and all other lines in 
RPMI-1640 medium (Biosera, East Sussex, UK) supplemented with 2mM L-glutamine, penicillin (50U) 
/ streptomycin (50µg) and 10% v/v foetal calf serum (Biosera, East Sussex, UK) at 37°C with 5% CO 2. 
 
Primary CD34+ cells.  Primary CML cells were obtained with written informed consent in accordance 
with the Declaration of Helsinki, from peripheral blood leukapheresis samples from newly diagnosed 
patients with chronic phase (CP) CML.  Both the Royal Liverpool University Hospital and Glasgow 
Royal Infirmary’s Local Research Ethics Committee approved the use of human tissue in this study 
protocol.  CD34+ cells enriched by positive selection (>95%) were cultured in growth factor 
supplemented serum free medium as previously described (8). For quantitative polymerase chain 
reaction (qPCR) analysis, RNA (1µg aliquots) derived from normal CD34+ cells isolated from mobilized 
peripheral blood (mPB), was purchased from Cambrex Bioscience (Wokingham, UK) and Stem Cell 
Technologies UK (Vancouver, Canada).  
 
Cellular analysis.  Intracellular phospho-CrkL (p-CrkL), annexin V/propidium iodide and 
carboxyfluorescein succinimidyl ester (CFSE) staining were performed and analysed by flow cytometry 
as described previously (22, 23). Cell viability and counts were determined by dye exclusion. 
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Efflux studies.  The efflux protocol was a modification of that previously described (24).  Cells were 
incubated with appropriate concentrations of inhibitors/TKI as required for 15min to block pump activity 
before the incubation with fluorescent substrates for a further 30min. Cells were washed and 
incubated ± inhibitors/TKI for 1h to allow efflux before washing in ice-cold medium for analysis (8). 
Fluorescent substrates and inhibitors, respectively, were Rhodamine-123 (0.5µg/mL; Invitrogen, 
Paisley, UK) and PSC833 (5µM) for MDR1; Fluo3-AM (5µg/mL; Axxora, Nottingham, UK) and MK571 
(30µM; Axxora) for MRP1; BODIPY-Prazosin (200nM; Axxora, Nottingham, UK) and fumitremorgin C 
(FTC, 10µM; Axxora, Nottingham, UK) for ABCG2. Retention values were calculated by designating 
the level of fluorescence in the presence of the known inhibitor as 100%.  
 
Radio-labelled intracellular uptake and retention (IUR) assay using KCL22 cells. Drug transport 
studies of 14C-radiolabelled nilotinib (4 and 1µM: spanning peak and trough plasma levels respectively 
of a 400mg twice daily dose) were performed using high expressing hOCT1 transfected KCL22 cells, 
with or without hOCT1 and MDR1 inhibitors/substrates.  MDR1 inhibitors used were:  PSC833 (10µM); 
verapamil (500µM); and tariquidar (500nM).  OCT1 inhibitors/substrates used were:  prazosin 
(100µM); amantadine (500µM) and TEA (5µM).  After drug treatment cells were lysed before 
scintillation counting as previously published (16). Cell-associated nilotinib levels were expressed as 
ng per million cells. 
 
Measurement of transepithelial drug transport by MDR1. Vectorial MDR1 efflux studies were 
performed on MDCKII cells as previously described (16).  Cells were seeded at 1.5-2 x 106 cells per 
well onto 24mm diameter, 0.4µm pore size, polycarbonate transwell membrane inserts (Appleton 
Woods, UK).  Transepithelial electrical resistance (TEER) was measured, after 5 to 6 days, using a 
Millicell-ERS Volt-ohmmeter (Millipore, UK) to determine a confluent monolayer. The blank membrane 
resistance was subtracted from monolayer resistance then multiplied by the surface area (4.67cm2) to 
calculate TEER in Ω x cm2.  Monolayers with TEER values greater than 200 Ω x cm2 were used.  Cells 
were co-incubated throughout with 3H-mannitol (0.05µCi/mL) (Sigma, Poole, UK) to ensure monolayer 
integrity. 
DAVIES et al.                            NILOTINIB TRANSPORT IN CML  
 6
Monolayers were washed with HBSS and allowed to equilibrate for 30min in transport medium 
(1% v/v HEPES in HBSS) before incubation with 14C-imatinib (5µM) or 14C-nilotinib (4µM) for 4h.  
Radioactivity was measured in medium from donor and acceptor compartments by liquid scintillation 
spectrometry.  TKI movement was calculated as a percentage of radioactivity transported across the 
monolayer (25).  For MDR1 inhibition studies MDCKII-MDR1 cells were pre-incubated with PSC833 
(10µM) 30min prior to the addition of the radioactive TKIs, as described above. 
 
Distribution Coefficient (logD) / Lipophilicity Studies.  The lipophilicity of a compound is defined as 
the distribution coefficient (logD) in a biphasic system.  The logD of 14C-labelled nilotinib and imatinib 
were measured as described by Yunger and Cramer (26). In brief, equimolar quantities of the drugs 
(500nM) were suspended in 1ml transport medium then mixed vigorously for 15min with 1ml 1-octanol.  
The layers were separated by centrifugation at 2000rpm for 10min at room temperature.  Radioactivity 
was determined by scintillation counting of 500µL aliquots from both phases.  Results were derived 
from three experiments each consisting of four replicates.  The logD distribution coefficient was 
calculated as below where DPM represents disintegrations per minute:  
[DPM(octanol)]
[DPM(buffer)]
logD =    log
 
 
RESULTS AND DISCUSSION 
There has been much debate about the most suitable imatinib or nilotinib concentration for in 
vitro study that most closely represent clinically achievable levels.  In our recent preliminary work (27) 
we have shown that plasma levels of 2.7µg/mL are achieved 10h post 400mg imatinib; those taking 
600-800mg achieved imatinib plasma levels above 3µg/mL 10-16h post dose.  Therefore an imatinib 
plasma level of 5µM (2.95µg/mL) is clinically achievable.  Similarly, the use of 1 and 4µM nilotinib 
spans the upper and lower standard deviation range of serum steady state Cmax levels for the typical 
800mg daily dose (Novartis: data on file via personal communication with Dr P Manley, Novartis 
Pharma, 2008); and supported by plasma level data generated from patient pharmacokinetic (PK) 
profiles at the Royal Liverpool University Hospital. Based on these data we consider that our use of 
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these concentrations of TKI more closely mimics in vivo conditions than the use of low submicromolar 
concentrations that have been used in some other transport studies. 
 
Nilotinib is more lipophilic than imatinib and cellular accumulation is not dependent on active 
import by hOCT1. 
It has been demonstrated, by ourselves and others, that the response to imatinib both in vitro 
and in vivo is dependent on active uptake into the cells via the solute transporter hOCT1 (16, 19, 28).  
However, little is known about the mechanism by which nilotinib enters cells.  In the only previous 
study by White et al, unlike the effect on imatinib transport, inhibition of hOCT1 activity by prazosin did 
not decrease nilotinib uptake into CML cells (19).  Our data, using a stably transfected cell line model, 
extend this previous investigation and strongly support that hOCT1 is not involved in the import of 
nilotinib [Figure 1A&B].  We have also demonstrated that nilotinib uptake was not temperature 
dependent and occurred very rapidly reaching maximal levels by the first time point of 2min [Figure 
1A], consistent with our finding that nilotinib was more lipophilic than imatinib as measured by 
calculation of logD (2.4 versus 0.8, respectively) and therefore more likely to be taken up into the cells 
without active transport.  
The passive nature of this uptake was also demonstrated by data shown in Figure 1A which 
shows that nilotinib levels are unaffected by the level of expression of hOCT1. KCL22 cells transfected 
with hOCT1 were also exposed to nilotinib in the presence of the hOCT1 and 2 inhibitor amantadine or 
hOCT1 and 3 inhibitor prazosin; neither of which altered the uptake of nilotinib [Figure 1B].  The 
efficient 1 hour uptake of nilotinib in the absence of hOCT1 transport was confirmed at a functional 
level by measuring reduction in Bcr-Abl activity using p-CrkL as a surrogate marker (data not shown).  
Nilotinib did reproducibly reduce CrkL phosphorylation to a greater extent than imatinib, but in contrast 
to imatinib treatment, p-CrkL levels were not altered by the over-expression of hOCT1 in KCL22 cells 
[imatinib-treated pcDNA 78.6±12.6% v hOCT1 39.8±5.8%; P = 0.0185: nilotinib-treated pcDNA 
37.4±8.0% v hOCT 49.4±14.1%; P = 0.477. n = 6, ±SEM]. 
Interestingly our studies show that nilotinib can reduce uptake of TEA, a known hOCT1 
substrate, suggesting nilotinib disrupts hOCT1 transport function [Figure 1C].  We have also observed 
such activity for imatinib, however, nilotinib was more potent than imatinib in this regard. In isolation 
these data may suggest that nilotinib reduces TEA uptake as a competitive substrate, however as we 
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did not find any evidence that nilotinib is a substrate for hOCT1 [Figures 1A&B] we therefore consider 
that nilotinib is impeding TEA uptake by inhibiting the function of the transporter.  Therefore, drugs 
transported by hOCT1 would be blocked when co-administered with nilotinib.  This is further supported 
by our observation that nilotinib, at 1 and 4µM, abolished 14C-imatinib uptake in KCL22-hOCT1 cells 
(data not shown) and similar data have been reported by White et al (28). Given the ability of nilotinib 
to inhibit hOCT1, one must consider the possibility of drug-drug interactions. For instance, the anti-
diabetic agent metformin, is a substrate for hOCT1 transport (20); and therefore co-administration with 
nilotinib may inhibit metformin uptake which may have a clinically relevant impact on the control of 
glucose levels in diabetic CML patients taking nilotinib.  
 Based on the findings from this study, we conclude that nilotinib enters cells passively and 
can accumulate readily. Hence, unlike imatinib where modulation of uptake may improve the 
performance of the drug, it is unlikely that the intracellular concentration of nilotinib can be further 
increased by solute carrier modulation.  
 
Nilotinib is not effluxed by clinically relevant drug transporters 
In addition to examining drug uptake, there have been a number of contradictory studies 
investigating whether efflux transporters may limit the intracellular concentration and thus efficacy of 
imatinib (8-16, 29). To date the transporter that has been studied in most detail is ABCG2.  There is 
still no consensus on whether imatinib is a substrate or inhibitor for this protein however, collation of all 
the data supports the proposal of a dual activity whereby at low concentration (≤0.8µM) imatinib is a 
substrate and at higher concentrations it is an inhibitor of ABCG2 (9-11). Our own studies have shown 
that ABCG2 is over-expressed on CML CD34+ cells but that inhibition of efflux does not increase the 
effect of imatinib in this population which contains the CML stem cells (8). There have been few 
comprehensive studies on the interaction of imatinib and MDR1 cells in primary CML stem cells but 
cell line studies suggest it may be an MDR1 substrate (13, 14, 29). Our most recent work in primary 
CML CD34+ cells suggests firstly that MDR1 is expressed at very low levels in these cells, and 
secondly, that as the interaction of imatinib with MDR1 is as an inhibitor, transporter blockade is 
unlikely to be significant in this population (15).  
We found that nilotinib was not a substrate for any of the transporters tested in cell line 
models. In a vectorial transport assay, based on MDCKII cells engineered to over-express MDR1 
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apically whereby basal to apical exceeds apical to basal transport of MDR1 substrates, the transport 
of 14C-nilotinib across the monolayer in either direction was slightly decreased compared to imatinib 
[Figure 1D] and was not altered by the MDR1 inhibitor PSC833.  This lack of efflux by MDR1 was 
confirmed by the uptake and retention of nilotinib into KCL22 cells being unaffected by the MDR1 
inhibitors verapamil, PSC833 or tariquidar [Figure 1E].  We also used cell lines expressing different 
transporters in 14C-nilotinib uptake assays [Figure 2; upper panels] and in fluorescent substrate assays 
[Figure 2; lower panels].  Expression of MDR1, MRP1 or ABCG2 did not decrease the retention of 14C-
nilotinib, and furthermore inhibition of these efflux transporters with the specific inhibitors PSC833, 
MK571 or FTC respectively, did not cause any increase in drug retention [Figure 2; upper panels].  
However, in substrate efflux assays [Figure 2; lower panels] nilotinib significantly reduced efflux via 
MDR1 or ABCG2 and had a small inhibitory effect on MRP1 mediated efflux.  Therefore, whilst 
nilotinib is not a substrate for any of these transporters it can inhibit efflux via MDR1 or ABCG2. 
In order to investigate whether the poor response of CML CD34+ cells to nilotinib was due to 
low intracellular accumulation we looked at the expression of mRNA using qPCR for the three main 
clinically relevant transporters MDR1, MRP1 and ABCG2 that have been previously associated with 
drug resistance in leukaemia (30, 31).  We found that all three efflux transporters are expressed in 
CD34+ CML cells, however hOCT1 was below the level of detection in normal or CML CD34+ cells.  
MRP1 was detected at levels similar to those in normal CD34+ cells (108%), ABCG2 at higher levels 
(291%) as previously reported (8) and surprisingly, MDR1 was found to be expressed at a lower level 
in CML (13.5%) than normal CD34+ cells (Supplemental Data, Table 1).  MDR1 expression is often 
elevated in leukaemia and indeed has been found at higher levels on CML versus normal 
mononuclear cells (MNC) and in primary cells from patients with advanced phase CML (32), however 
this is not the case in the more primitive population in CP, underlining the key differences depending 
on cell type and disease phase.  
As all three efflux transporters were expressed, we assessed the interaction of nilotinib in 
primary CML CD34+ cells and tested the effect of inhibiting the transporters whilst these cells were 
treated with nilotinib. As shown in the top and middle panels of Figure 3, CML CD34+ cells 
demonstrated moderate substrate efflux via MDR1 (56.2 ± 11.5% retention) and ABCG2 (54.4 ± 
19.3% retention), but a very high level of MRP1 activity (4.89 ± 0.22% retention). These levels of 
activity correlate with the relative levels of mRNA for these transporters (Supplemental Data, Table 1).  
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When the known inhibitors were replaced with increasing doses of nilotinib [lower panel Figure 3] the 
TKI had no significant effect on MDR1 activity (70.6 ± 9.8% retention at 5µM); however, it was difficult 
to determine reproducibility due to the low control level of MDR1-mediated efflux. Similarly, efflux of 
BODIPY-prazosin via ABCG2 was not seen to any significant degree within this cohort of samples; the 
expression level of ABCG2 was also lower than we have reported for a previous cohort (8).  We were 
therefore unable to confirm the inhibitory effect seen with nilotinib in ABCG2 over-expressing lines in 
CML CD34+ cells.  However, CML CD34+ cells demonstrated a high degree of efflux of Fluo3-AM via 
MRP1 (4.89 ± 0.22% retention) and this efflux was slightly reduced by nilotinib (15.3 ± 6.0% retention 
at 5µM vs. 4.89 ± 0.22% control, not statistically significant).  Additionally, CD34+ CML cells were 
incubated in nilotinib with and without the individual inhibitors to directly assess the effect of 
transporter inhibition on the intracellular concentration by high pressure liquid chromatography (HPLC) 
analysis.  The individual inhibitors had no effect on this concentration nor did the combined use of all 
three inhibitors (data not shown).  Therefore, as seen in the cell lines, whilst nilotinib may have some 
inhibitory effect on MDR1 and ABCG2 (and hOCT1) it is not a substrate for these transporters and the 
intracellular concentration of this TKI is not controlled by any of the transporters tested. 
These findings are somewhat different to those of Mahon et al, who have reported that 
nilotinib resistant cell lines have elevated MDR1 expression (33). However, those studies made use of 
cell lines that had developed resistance after prolonged exposure to nilotinib rather than by over-
expression of specific transporters, this may be why it was not possible to fully differentiate between 
MDR1 mediated effects and other mechanisms of resistance such as Bcr-Abl over expression or lyn 
activity. Also, unlike the previous study we have directly measured drug accumulation in addition to 
cell death and MDR1 inhibitor effects and our finding that nilotinib is not a substrate for MDR1 is in 
agreement with the previous report of White and colleagues (28) who found that inhibition of MDR1 in 
MNC from CP CML patients did not increase the intracellular concentration of nilotinib, nor did MDR1 
expression protect cell lines from nilotinib induced death. 
Another previous study suggested that nilotinib is transported by ABCG2 at low concentrations 
(18), but the study was performed on cell lines and normal stem cells.  Furthermore, the 
concentrations at which nilotinib was transported were in the low nanomolar range which were far 
below even trough levels measured in patient serum.  We have used seemingly high concentrations of 
nilotinib throughout these experiments primarily because we have previously seen that even these 
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concentrations do not kill CD34+ cells, and it is this insensitivity in the stem cell population that we 
specifically want to investigate.  Additionally, the doses we used (1-5µM) are similar to the observed 
peak values of 3.6µM achieved by standard 400mg twice daily dosing.  However, CML stem cells may 
reside within bone marrow niches and therefore not be exposed to serum concentrations of drug. It is 
not practical to measure the amount of drug within specific niches, but we have previously found that 
there is no significant difference in the concentration of imatinib found in bone marrow extracts and 
peripheral blood samples (Jorgensen & Holyoake, unpublished data). We have not made these 
measurements for nilotinib but given the similar pharmacokinetic data for nilotinib and imatinib we 
suggest that the distribution of nilotinib would not be significantly lower in bone marrow than blood but 
we can not exclude the possibility of highly localised depletion in the defined stem cell niche.  Our 
finding that nilotinib is not a substrate for MDR1 is in agreement with the previous report of White and 
colleagues (28) who found that inhibition of MDR1 in MNC from CP CML patients did not increase the 
intracellular concentration of nilotinib, nor did MDR1 expression protect cell lines from nilotinib induced 
death. 
 
Transporter activity does not modulate the effect of nilotinib on primary chronic myeloid 
leukaemia CD34+ cells 
The proposal that drug transport is not responsible for the insensitivity of CD34+ cells to 
nilotinib is further supported by our findings from co-treatment experiments.  Blockade of ABCG2 or 
MRP1, with FTC or MK571 respectively, did not potentiate the effect of nilotinib on CD34+ CML cells 
over a period of 72h treatment [Figure 4].  P-CrkL assays at 72h showed that nilotinib significantly 
reduced the activity of Bcr-Abl in these cells (62.2 ± 12.21% at 72h) compared to control but this 
reduction was not potentiated by inhibition of efflux transporters [Figure 4A].  Similarly, when the total 
number of cells remaining in the cultures was assessed at 72h [Figure 4B] nilotinib treatment resulted 
in reduced cell numbers due to both anti-proliferative and pro-apoptotic effects as expected.  Neither 
MRP1 nor ABCG2 inhibition further decreased cell numbers.  However, the effect of MDR1 inhibition 
with PSC833 was less clear.   
PSC833 has previously been found to have unacceptable toxicity in vivo (34), resulting in early 
termination of trials using this agent.  Our preliminary experiments demonstrated that the standard 
concentration of 10µM used for cell line studies caused significant apoptosis and was profoundly 
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cytostatic in CML CD34+ cells (data not shown).  Therefore, we reduced the concentration to 5µM 
which still gave full inhibition of Rhodamine-123 efflux in cell lines but had a less detrimental effect on 
CD34+ cells. However, we still saw an increase in cell death and some anti-proliferative effect when 
the CML CD34+ cells were treated with PSC833 alone; this effect was maintained in the presence of 
nilotinib and therefore the combination resulted in a further reduction in the number of cells remaining 
in culture.  Whilst this result initially seems to demonstrate that MDR1 inhibition enhances the effect of 
nilotinib we did not see an additive effect on the reduction of Bcr-Abl activity by p-CrkL assay nor did 
we measure any increase in the intracellular concentration of nilotinib by radio-labelled or HPLC 
analyses.  We conclude, therefore that the effect of PSC833 is not connected to transport of nilotinib. 
The data may indicate that there is an endogenous substrate that accumulates when MDR1 is 
inhibited which is toxic to the cells, or simply that PSC833 has a non–specific toxic effect – we 
consider the latter to be most likely.  In support of this, Mahon and colleagues also reported 
unexpected results when using PSC833 with CML cells (29). We also suggest that this non-specific 
effect may underlie some of the confusion about the effect of MDR1 inhibition in previous cell line 
studies of imatinib. In such studies, PSC833 appeared to increase the response to nilotinib and 
imatinib however, detailed analyses including determination of drug accumulation and activity, are 
required to deconvolute this effect and have not been performed in many of these studies. 
Finally, we looked at the number of CD34+ cells that remained quiescent in culture during the 
treatment [Figure 4C]; this population represents the putative CML stem cell population which is 
resistant to TKI and may be responsible for clinical persistence of the disease.  As we have reported 
previously, nilotinib increased the number of these cells [Figure 4C] however, there was no significant 
effect on this population in response to transporter inhibition alone or in combination with nilotinib. 
In conclusion, we have found no evidence for either active uptake of nilotinib via hOCT1 or 
efflux via MDR1, MRP1 or ABCG2.  It is therefore unlikely that differential expression or function of 
these transporters will have any effect on the clinical response to this drug in either MNC or the more 
resistant CD34+ stem cell population.  However, nilotinib appears to be an inhibitor of both influx and 
efflux pumps, and is therefore liable to be involved in drug-drug interactions. 
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TITLES AND LEGENDS TO FIGURES 
Figure 1.  Nilotinib is neither imported by hOCT1  nor effluxed by MDR1. 
A. Nilotinib transport is not influenced by hOCT1:  Parental (parent), hOCT1 transfected (OCT1) and 
empty vector transfected (pcDNA) KCL22 cells were treated with 14C-nilotinib (4µM) for up to 2h.  
Mean data of 5 experiments ±SEM.  B. Nilotinib is not a substrate for hOCT1 influx: hOCT1 and empty 
vector transfected KCL22 cells were treated for 30min with 1 or 4µM 14C-nilotinib or co-incubated with 
OCT1 inhibitors: - 500µM amantadine (AMT) and 100µM prazosin (PRZ); and 5µM 
tetraethylammonium bromide (TEA), an OCT1 substrate.  Mean data of 5 experiments; ±SEM. C. 
Competitive uptake of TEA with TKIs:  KCL22 cells transfected with hOCT1 cells were incubated with 
14C-labelled TEA (5µM).  TEA influx via OCT1 was competed for by imatinib (IM) (5µM) and nilotinib 
(NIL) (4µM). AMT (500µM) was used as a positive control for blocking TEA uptake.  Mean data of 5 
experiments ±SEM. D.  Nilotinib is not transported by MDR1 in cell lines Efflux of 14C-nilotinib (4µM) in 
parental (MDCKII) and MDR1-transfected (MDR1) MDCKII cells pre-incubated with PSC833 (10µM) 
(MDR1 + PSC).  A-B = apical to basal transport; B-A = basal to apical transport.  Mean data of 5 wells; 
± SEM. E. KCL22 parental cells treated for 30min with 1 or 4µM 14C-nilotinib and co-incubated with 
MDR1 inhibitors: - 10µM PSC833; 500nM tariquidar (TQD); 500µM verapamil (VPL).  Mean data of 5 
experiments; ± SEM.  
Figure 2.  Nilotinib is not a substrate for MDR1, MRP1 or ABCG2 in cell lines.  
Top panels: Accumulation of 14C-nilotinib in cell lines. Cell lines were incubated for 2h with 5µM 14C-
nilotinib. Top left: K562-WT or K562-MDR1 cells in the presence or absence of 5µM PSC. Top mid: 
K562-WT or K562-MRP1 cells in the presence of absence of 30 or 100µM MK571. Top right: AML3 
or AML6.2 cells, which over express ABCG2, in the presence of absence of 10µM FTC. All data are 
mean ± SEM of 3 separate experiments performed in duplicate.  
Lower panels: Substrate Displacement Assay to show interaction of nilotinib with transporters. Lower 
left: K562-MDR1 cells were loaded with 0.5µg/mL Rhodamine-123 alone or in the presence of 5µM 
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PSC833 or increasing concentrations of nilotinib (0.1 to 5µM). Lower mid: K562-WT (MRP1+) cells 
were loaded with 5µg/mL Fluo3-AM alone or in the presence of 30µM MK571 or increasing 
concentrations of nilotinib (0.1 to 5µM). Lower right: AML6.2 (ABCG2+) cells were loaded with 200nM 
BODIPY-Prazosin alone or in the presence of 10µM FTC or increasing concentrations of nilotinib (0.1 
to 5µM). In all lower panels, unstained cells are denoted by black fill, with substrate by light grey fill, 
with substrate + inhibitor by dark grey fill, with substrate + nilotinib by black line no fill. Representative 
examples are shown and all experiments were performed on 3 independent samples in duplicate. 
Figure 3.  Nilotinib is not a substrate for MDR1, MRP1 or ABCG2 in CP CML CD34 cells.  
Top panels: Accumulation of 14C-nilotinib in CD34+ CML cells.  CD34+ cells from patient in CP were 
incubated for 2h with 5µM 14C-nilotinib ± 5µM PSC833 (top left), 30µM MK571 (top mid) or 10µM 
FTC (top right). All data are mean ± SEM of duplicate analyses of 3 separate patient samples.  
Middle panels: Substrate Displacement Assay to show efflux via transporters. CML CD34+ cells were 
loaded with 0.5µg/mL Rhodamine-123 alone or in the presence 5µM PSC833 (middle left); 5µg/mL 
Fluo3-AM alone or in the presence 30µM MK571 (middle mid); 200nM BODIPY-Prazosin alone or in 
the presence of 10µM FTC (middle left).  
Lower Panels: Substrate Displacement Assay to show interaction of nilotinib with transporters. As for 
middle panels but with the addition of nilotinib in place of PSC833, MK571 or FTC.  
In middle and lower panels: unstained cells are denoted by black fill; cells with substrate alone by 
light grey fill, with substrate + inhibitor by dark grey fill, with substrate + nilotinib by black lines no fill. 
Representative examples are shown and all experiments were performed on at least 3 independent 
samples in duplicate. 
Figure 4.  Transporter inhibition does not increase the effect of nilotinib in CD34+ CML cells. 
CML CD34+ cells from patients in CP were analysed after 72h in culture with no drug or with 5µM 
nilotinib ± 5µM PSC833, 30µM MK571 or 10µM FTC as denoted. A. The percentage level of p-CrkL 
was determined by flow cytometry to measure the geometric mean fluorescence with no drug control 
cells considered to be maximally phosphorylated. Data are mean ± SEM of 5 patient samples 
performed in duplicate. B. the total number of cells was assessed by cell counting; data are mean ± 
SEM of between 4 and 12 patient samples performed in duplicate. C. The number of quiescent CD34+ 
cells (putative CML stem cells) remaining was calculated based on the use of CFSE to track cell 
division and FACS analysis of CD34+ at the end of the culture period. Data are mean ± SEM of 2 
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samples for nilotinib + MK571, and 4 to 10 samples for all other conditions, each performed in 
duplicate. 
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